BioCentury | Nov 24, 2014
Clinical News

Plasma-derived Alpha-1 antitrypsin: Phase I/II data

...the historical control group. Data were presented at the American Heart Association meeting in Chicago. Omni Bio Pharmaceutical Inc....
BioCentury | Aug 18, 2014
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Fort Collins, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Jack Riccardi as CFO, effective Sept. 1, formerly CFO and partner of Green Street Ventures WIR Staff Infectious Transplant...
BioCentury | May 12, 2014
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Bruce Forrest as chief development officer WIR Staff Infectious Transplant...
BioCentury | Apr 28, 2014
Financial News

Omni Bio Pharmaceutical completes private placement of convertible notes

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Date completed: 4/24/14 Type: Private placement of convertible notes Raised: $2 million Shares outstanding prior: 38.7 million Investor: Bohemian Investments Note: The note...
BioCentury | Jul 22, 2013
Clinical News

Plasma-derived Alpha-1 Antitrypsin: Phase II started

...Society (LLS) (White Plains, N.Y.) are providing the majority of the funding for the trial. Omni Bio Pharmaceutical Inc....
BioCentury | Apr 8, 2013
Clinical News

Omni Bio Pharmaceutical preclinical data

...to Kineret from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) for RA and undisclosed orphan indications. Omni Bio Pharmaceutical Inc....
BioCentury | Dec 24, 2012
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Bruce Schneider as CEO and a director, effective Jan. 1, 2013, formerly EVP and chief of operations at Wyeth , which Pfizer Inc....
BioCentury | Feb 28, 2011
Company News

Omni management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine, Transplant Hired: James Crapo as CEO, formerly CEO of Aeolous Pharmaceuticals Inc.; he replaces acting CEO Charles Dinarello, who will become CSO and CMO...
BioCentury | Feb 25, 2011
Company News

Omni names Crapo CEO

...Diabetes, infectious and transplant company Omni Bio Pharmaceutical Inc. (OTCBB:OMBP) hired James Crapo as CEO, effective March 1. Crapo...
BioCentury | Oct 25, 2010
Clinical News

Alpha-1 Antitrypsin: Phase I/II started

...trial in up to 50 newly-diagnosed Type I diabetics to evaluate AAT for 2 years. Omni Bio Pharmaceutical Inc....
Items per page:
1 - 10 of 11
BioCentury | Nov 24, 2014
Clinical News

Plasma-derived Alpha-1 antitrypsin: Phase I/II data

...the historical control group. Data were presented at the American Heart Association meeting in Chicago. Omni Bio Pharmaceutical Inc....
BioCentury | Aug 18, 2014
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Fort Collins, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Jack Riccardi as CFO, effective Sept. 1, formerly CFO and partner of Green Street Ventures WIR Staff Infectious Transplant...
BioCentury | May 12, 2014
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Bruce Forrest as chief development officer WIR Staff Infectious Transplant...
BioCentury | Apr 28, 2014
Financial News

Omni Bio Pharmaceutical completes private placement of convertible notes

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Date completed: 4/24/14 Type: Private placement of convertible notes Raised: $2 million Shares outstanding prior: 38.7 million Investor: Bohemian Investments Note: The note...
BioCentury | Jul 22, 2013
Clinical News

Plasma-derived Alpha-1 Antitrypsin: Phase II started

...Society (LLS) (White Plains, N.Y.) are providing the majority of the funding for the trial. Omni Bio Pharmaceutical Inc....
BioCentury | Apr 8, 2013
Clinical News

Omni Bio Pharmaceutical preclinical data

...to Kineret from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) for RA and undisclosed orphan indications. Omni Bio Pharmaceutical Inc....
BioCentury | Dec 24, 2012
Company News

Omni Bio Pharmaceutical management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine/Metabolic, Transplant Hired: Bruce Schneider as CEO and a director, effective Jan. 1, 2013, formerly EVP and chief of operations at Wyeth , which Pfizer Inc....
BioCentury | Feb 28, 2011
Company News

Omni management update

Omni Bio Pharmaceutical Inc. (OTCBB:OMBP), Greenwood Village, Colo. Business: Infectious, Endocrine, Transplant Hired: James Crapo as CEO, formerly CEO of Aeolous Pharmaceuticals Inc.; he replaces acting CEO Charles Dinarello, who will become CSO and CMO...
BioCentury | Feb 25, 2011
Company News

Omni names Crapo CEO

...Diabetes, infectious and transplant company Omni Bio Pharmaceutical Inc. (OTCBB:OMBP) hired James Crapo as CEO, effective March 1. Crapo...
BioCentury | Oct 25, 2010
Clinical News

Alpha-1 Antitrypsin: Phase I/II started

...trial in up to 50 newly-diagnosed Type I diabetics to evaluate AAT for 2 years. Omni Bio Pharmaceutical Inc....
Items per page:
1 - 10 of 11